Floatz logo

Ssgj-706

Gastric/Gastroesophageal Junction Adenocarcinoma

Shenyang Sunshine Pharmaceutical Co., LTD.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

112 Active assets in the Gastric/Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB

View all 50 →

Same molecule, other indications

Ssgj-706 is also rated in:

colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
esophageal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →